Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. (2nd January 2018)

• Record Type: Journal Article
• Authors: Chang, Andres; Schlafer, Danielle; Flowers, Christopher R.; Allen, Pamela B.
• Is Part Of: Expert opinion on investigational drugs. Volume 27:Number 1(2018)
• Page Start: 55
• Page End: 70
• Publication Date: 2018-01-02
• Subjects: PD-1 -- PD-L1 -- non-Hodgkin lymphoma -- Hodgkin lymphoma -- immunotherapy -- PD-1 inhibitor; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2018.1416091
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered : We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion : We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.